How much profit has HLB Therapeutics Co made this year?
HLB Therapeutics Co has made -2.3 B KRW this year.
HLB Therapeutics Co Net Income 2024
HLB Therapeutics Co Net Income
-2.3 B KRW
Ticker
115450.KQ
ISIN
KR7115450009
In 2024, HLB Therapeutics Co's profit amounted to -2.3 B KRW, a -79.72% increase from the -11.35 B KRW profit recorded in the previous year.
The HLB Therapeutics Co Net Income history
| YEAR | NET INCOME (undefined KRW) |
|---|---|
| 2023 | -2.3 |
| 2022 | -11.35 |
| 2021 | -17.2 |
| 2020 | -16.9 |
| 2019 | -16.42 |
| 2018 | 4.58 |
| 2017 | -4.82 |
| 2016 | -5.2 |
| 2015 | -4.3 |
| 2014 | -1.61 |
| 2013 | -3.94 |
| 2012 | -6.24 |
| 2011 | -33.16 |
| 2010 | 4.11 |
| 2009 | 3.8 |
| 2008 | 1.94 |
| 2007 | 2.79 |
| 2006 | 3.22 |
| 2005 | 1.65 |
HLB Therapeutics Co Revenue, EBIT, Net Income KR7115450009 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into HLB Therapeutics Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by HLB Therapeutics Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects HLB Therapeutics Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of HLB Therapeutics Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into HLB Therapeutics Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing HLB Therapeutics Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on HLB Therapeutics Co’s growth potential.
HLB Therapeutics Co Revenue, EBIT and net profit per share
| Date | HLB Therapeutics Co Revenue | HLB Therapeutics Co EBIT | HLB Therapeutics Co Net Income |
|---|---|---|---|
| 2023 | 53.75 B undefined | -8.7 B undefined | -2.3 B undefined |
| 2022 | 42.4 B undefined | -7.51 B undefined | -11.35 B undefined |
| 2021 | 43.59 B undefined | -11.09 B undefined | -17.2 B undefined |
| 2020 | 42.93 B undefined | -11.27 B undefined | -16.9 B undefined |
| 2019 | 58.97 B undefined | -8.83 B undefined | -16.42 B undefined |
| 2018 | 43.59 B undefined | -3.16 B undefined | 4.58 B undefined |
| 2017 | 17.15 B undefined | -4.49 B undefined | -4.82 B undefined |
| 2016 | 17.71 B undefined | -4.04 B undefined | -5.2 B undefined |
| 2015 | 16.78 B undefined | -3.14 B undefined | -4.3 B undefined |
| 2014 | 17.62 B undefined | -875 M undefined | -1.61 B undefined |
| 2013 | 20.86 B undefined | -1.81 B undefined | -3.94 B undefined |
| 2012 | 59.3 B undefined | -906 M undefined | -6.24 B undefined |
| 2011 | 15.78 B undefined | 762 M undefined | -33.16 B undefined |
| 2010 | 11.32 B undefined | 3.49 B undefined | 4.11 B undefined |
| 2009 | 10.94 B undefined | 3.04 B undefined | 3.8 B undefined |
| 2008 | 9.07 B undefined | 1.46 B undefined | 1.94 B undefined |
| 2007 | 8.88 B undefined | 2.7 B undefined | 2.79 B undefined |
| 2006 | 8.14 B undefined | 3.18 B undefined | 3.22 B undefined |
| 2005 | 4.33 B undefined | 1.51 B undefined | 1.65 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 4.33 B KRW | 1.51 B KRW | 1.65 B KRW |
| 2006 | 8.14 B KRW | 3.18 B KRW | 3.22 B KRW |
| 2007 | 8.88 B KRW | 2.7 B KRW | 2.79 B KRW |
| 2008 | 9.07 B KRW | 1.46 B KRW | 1.94 B KRW |
| 2009 | 10.94 B KRW | 3.04 B KRW | 3.8 B KRW |
| 2010 | 11.32 B KRW | 3.49 B KRW | 4.11 B KRW |
| 2011 | 15.78 B KRW | 762 M KRW | -33.16 B KRW |
| 2012 | 59.3 B KRW | -906 M KRW | -6.24 B KRW |
| 2013 | 20.86 B KRW | -1.81 B KRW | -3.94 B KRW |
| 2014 | 17.62 B KRW | -875 M KRW | -1.61 B KRW |
| 2015 | 16.78 B KRW | -3.14 B KRW | -4.3 B KRW |
| 2016 | 17.71 B KRW | -4.04 B KRW | -5.2 B KRW |
| 2017 | 17.15 B KRW | -4.49 B KRW | -4.82 B KRW |
| 2018 | 43.59 B KRW | -3.16 B KRW | 4.58 B KRW |
| 2019 | 58.97 B KRW | -8.83 B KRW | -16.42 B KRW |
| 2020 | 42.93 B KRW | -11.27 B KRW | -16.9 B KRW |
| 2021 | 43.59 B KRW | -11.09 B KRW | -17.2 B KRW |
| 2022 | 42.4 B KRW | -7.51 B KRW | -11.35 B KRW |
| 2023 | 53.75 B KRW | -8.7 B KRW | -2.3 B KRW |
HLB Therapeutics Co stock margins KR7115450009 ·
The HLB Therapeutics Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HLB Therapeutics Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HLB Therapeutics Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the HLB Therapeutics Co's sales revenue. A higher gross margin percentage indicates that the HLB Therapeutics Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the HLB Therapeutics Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the HLB Therapeutics Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the HLB Therapeutics Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the HLB Therapeutics Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the HLB Therapeutics Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
HLB Therapeutics Co Margin History
| HLB Therapeutics Co Gross margin | HLB Therapeutics Co Profit margin | HLB Therapeutics Co EBIT margin | HLB Therapeutics Co Profit margin |
|---|---|---|---|
| 2023 | 13.89 % | -16.19 % | -4.28 % |
| 2022 | 20.8 % | -17.7 % | -26.78 % |
| 2021 | 11.78 % | -25.44 % | -39.46 % |
| 2020 | 15.32 % | -26.25 % | -39.37 % |
| 2019 | 9.32 % | -14.98 % | -27.85 % |
| 2018 | 12.42 % | -7.24 % | 10.5 % |
| 2017 | 14.94 % | -26.18 % | -28.08 % |
| 2016 | 18.61 % | -22.81 % | -29.36 % |
| 2015 | 19.32 % | -18.73 % | -25.63 % |
| 2014 | 26.17 % | -4.97 % | -9.13 % |
| 2013 | 15.69 % | -8.68 % | -18.86 % |
| 2012 | 17.04 % | -1.53 % | -10.51 % |
| 2011 | 29.2 % | 4.83 % | -210.14 % |
| 2010 | 53.14 % | 30.81 % | 36.3 % |
| 2009 | 47.56 % | 27.74 % | 34.73 % |
| 2008 | 34.31 % | 16.05 % | 21.35 % |
| 2007 | 46.6 % | 30.4 % | 31.38 % |
| 2006 | 55.34 % | 39.07 % | 39.52 % |
| 2005 | 61.43 % | 34.9 % | 38.23 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 61.43 % | 34.9 % | 38.23 % |
| 2006 | 55.34 % | 39.07 % | 39.52 % |
| 2007 | 46.6 % | 30.4 % | 31.38 % |
| 2008 | 34.31 % | 16.05 % | 21.35 % |
| 2009 | 47.56 % | 27.74 % | 34.73 % |
| 2010 | 53.14 % | 30.81 % | 36.3 % |
| 2011 | 29.2 % | 4.83 % | -210.14 % |
| 2012 | 17.04 % | -1.53 % | -10.51 % |
| 2013 | 15.69 % | -8.68 % | -18.86 % |
| 2014 | 26.17 % | -4.97 % | -9.13 % |
| 2015 | 19.32 % | -18.73 % | -25.63 % |
| 2016 | 18.61 % | -22.81 % | -29.36 % |
| 2017 | 14.94 % | -26.18 % | -28.08 % |
| 2018 | 12.42 % | -7.24 % | 10.5 % |
| 2019 | 9.32 % | -14.98 % | -27.85 % |
| 2020 | 15.32 % | -26.25 % | -39.37 % |
| 2021 | 11.78 % | -25.44 % | -39.46 % |
| 2022 | 20.8 % | -17.7 % | -26.78 % |
| 2023 | 13.89 % | -16.19 % | -4.28 % |
HLB Therapeutics Co Aktienanalyse
What does HLB Therapeutics Co do?
HLB Therapeutics Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding HLB Therapeutics Co's Profit Margins
The profit margins of HLB Therapeutics Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of HLB Therapeutics Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating HLB Therapeutics Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
HLB Therapeutics Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When HLB Therapeutics Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about HLB Therapeutics Co stock
How has the profit developed compared to last year?
The profit has increased by -79.72% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does HLB Therapeutics Co publish its earnings?
HLB Therapeutics Co publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of HLB Therapeutics Co?
The profits of HLB Therapeutics Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of HLB Therapeutics Co?
You can learn more about the earnings of HLB Therapeutics Co by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does HLB Therapeutics Co pay?
Over the past 12 months, HLB Therapeutics Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, HLB Therapeutics Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of HLB Therapeutics Co?
The current dividend yield of HLB Therapeutics Co is .
When does HLB Therapeutics Co pay dividends?
HLB Therapeutics Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of HLB Therapeutics Co?
HLB Therapeutics Co paid dividends every year for the past 0 years.
What is the dividend of HLB Therapeutics Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is HLB Therapeutics Co located?
HLB Therapeutics Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von HLB Therapeutics Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of HLB Therapeutics Co from 10/7/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.
When did HLB Therapeutics Co pay the last dividend?
The last dividend was paid out on 10/7/2024.
What was the dividend of HLB Therapeutics Co in the year 2023?
In the year 2023, HLB Therapeutics Co distributed 0 KRW as dividends.
In which currency does HLB Therapeutics Co pay out the dividend?
The dividends of HLB Therapeutics Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von HLB Therapeutics Co
Our stock analysis for HLB Therapeutics Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Therapeutics Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- HLB Therapeutics Co Revenue
- HLB Therapeutics Co Net Income
- HLB Therapeutics Co P/E
- HLB Therapeutics Co P/S
- HLB Therapeutics Co EBIT
- HLB Therapeutics Co Dividend
- HLB Therapeutics Co Stocks
- HLB Therapeutics Co Market capitalization
- HLB Therapeutics Co Debt
- HLB Therapeutics Co Liabilities
- HLB Therapeutics Co Equity
- HLB Therapeutics Co AAQS
- HLB Therapeutics Co Employees
- HLB Therapeutics Co ROE
- HLB Therapeutics Co ROA
- HLB Therapeutics Co ROCE